AbbVie receives EC approval for Aquipta to treat migraine

RegulatoryapprovedAquiptaPositive

AI Analysis

Summary

AbbVie received European Commission approval for Aquipta, an oral CGRP receptor antagonist for acute migraine treatment in adults. This represents a regulatory milestone for the company's migraine therapy portfolio.

Outcome Details

European Commission approval for acute migraine treatment

Importance:7/10

Sentiment:

0.80

regulatory approvalEuropemigraineCGRP receptor antagonistoral treatment

Related Companies

$ABBV

Read the original article

Published by Pharmaceutical Technology on June 3, 2026 9:36 AM

Read Original